Mennenga SE

School of Life Sciences, Arizona State University, Tempe, AZ, USA.

7 papers · 1 preprint

ArticleMDMA

Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA.

Semple MG, Mennenga SE, Smith R +6

Europe PMC2026
PreprintMDMA

Brain-epigenome wide association study (BEWAS) on the effects of two emerging psychedelics: ketamine & MDMA

Semple MG, Mennenga SE, Smith R +6

Europe PMC2025
ArticlePsilocybin

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.

Pagni BA, Zeifman RJ, Mennenga SE +6

Europe PMC2025
ArticlePsilocybin

Editorial: What is up with psychedelics anyway?

Lewis CR, McMurray M, Mennenga SE +1

Europe PMC2023
ArticlePsilocybin

Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.

O'Donnell KC, Mennenga SE, Owens LT +6

Europe PMC2022
ArticlePsilocybin

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.

Bogenschutz MP, Ross S, Bhatt S +10

Europe PMC2022
ArticlePsilocybin

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

Ross S, Agin-Liebes G, Lo S +8

Europe PMC2021
ArticlePsilocybin

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.

Bogenschutz MP, Podrebarac SK, Duane JH +5

Europe PMC2018